Full text is available at the source.
CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia
CREBH links metabolic inflammation to excess liver production of fat particles and high blood fat levels
AI simplified
Abstract
CREBH enhances very-low-density lipoprotein (VLDL) assembly and secretion by upregulating apolipoprotein B (apoB) expression.
- Metabolic inflammation is associated with hyperlipidemia and cardiovascular disease.
- Overexpression of CREBH significantly increases both mRNA and protein levels of apoB in liver cells.
- Genetic depletion of CREBH in mice leads to reduced hepatic apoB mRNA expression.
- Acute fat loading in wild type mice results in increased secretion of triglyceride-rich lipoproteins, which is absent in CREBH-null mice.
- Inflammatory signals from TNFα and high-fat diets activate CREBH, enhancing apoB biosynthesis and VLDL secretion.
- CREBH is identified as the first transcription factor regulating apoB expression in response to metabolic inflammation.
AI simplified